Biomarin Pharmaceutical INC (BMRN) — SEC Filings

Overview

Biomarin Pharmaceutical INC (BMRN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 22, 2025: On December 19, 2025, BioMarin Pharmaceutical Inc. filed an 8-K report. The filing indicates that the report is a "Current Report" and is being filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The report's earliest event date is December 19, 2025, and it is categorized u

Sentiment Summary

Across 43 filings, the sentiment breakdown is: 3 bullish, 39 neutral, 1 mixed. The dominant filing sentiment for Biomarin Pharmaceutical INC is neutral.

Filing Type Overview

Biomarin Pharmaceutical INC (BMRN) has filed 25 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 2 SC 13G, 6 SC 13G/A with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (43)

• BioMarin Pharmaceutical Files Current Report — 8-K · Dec 22, 2025 Risk: low
  On December 19, 2025, BioMarin Pharmaceutical Inc. filed an 8-K report. The filing indicates that the report is a "Current Report" and is being filed pursuant t
• BioMarin Pharmaceutical Inc. Files 8-K Report — 8-K · Dec 19, 2025 Risk: low
  On December 19, 2025, BioMarin Pharmaceutical Inc. filed an 8-K report. The filing indicates the company entered into a material definitive agreement and includ
• BioMarin Pharma Reports Officer/Director Changes — 8-K · Dec 17, 2025 Risk: medium
  BioMarin Pharmaceutical Inc. filed an 8-K on December 17, 2025, reporting events as of December 11, 2025. The filing pertains to the departure of directors or c
• BioMarin Swings to Q3 Loss on Soaring R&D, Revenue Up 3.7% — 10-Q · Oct 28, 2025 Risk: high
  BioMarin Pharmaceutical Inc. reported a net loss of $30.744 million for the three months ended September 30, 2025, a significant decline from a net income of $1
• BioMarin Pharmaceutical Inc. Files 8-K — 8-K · Oct 27, 2025 Risk: low
  On October 27, 2025, BioMarin Pharmaceutical Inc. filed an 8-K report. The filing primarily concerns the company's financial condition and results of operations
• BioMarin Pharmaceutical Inc. Files 8-K — 8-K · Oct 7, 2025 Risk: low
  On October 7, 2025, BioMarin Pharmaceutical Inc. filed an 8-K report. The filing pertains to the company's results of operations and financial condition. No spe
• BioMarin Pharma Announces Board & Executive Changes — 8-K · Aug 11, 2025 Risk: low
  BioMarin Pharmaceutical Inc. announced on August 5, 2025, changes in its board of directors and executive compensation. The filing details the departure of cert
• BioMarin Q2 Revenue Jumps to $640M on Strong Product Sales — 10-Q · Aug 5, 2025 Risk: medium
  BioMarin Pharmaceutical Inc. reported total revenues of $640.0 million for the second quarter of 2025, a significant increase from $580.0 million in the second
• BioMarin Pharmaceutical Inc. Files 8-K on Financials — 8-K · Aug 4, 2025 Risk: low
  BioMarin Pharmaceutical Inc. filed an 8-K on August 4, 2025, reporting on its results of operations and financial condition. The filing includes financial state
• BioMarin CFO Departs, New CFO Appointed — 8-K · Aug 1, 2025 Risk: medium
  BioMarin Pharmaceutical Inc. announced on July 30, 2025, the departure of its Chief Financial Officer, Jeffrey Robert, effective August 1, 2025. The company als
• BioMarin Pharma Reports Director Changes and Officer Compensation Updates — 8-K · May 22, 2025 Risk: low
  On May 20, 2025, BioMarin Pharmaceutical Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates a
• BioMarin Pharmaceutical Inc. Files 8-K Report — 8-K · May 16, 2025 Risk: medium
  On May 16, 2025, BioMarin Pharmaceutical Inc. filed an 8-K report detailing a material definitive agreement. The filing also included Regulation FD disclosures
• BioMarin Pharmaceutical Q1 2025 Update — 10-Q · May 2, 2025 Risk: medium
  BioMarin Pharmaceutical Inc. reported its first quarter 2025 results, ending March 31, 2025. The company's financial performance for the period is detailed in t
• BioMarin Pharmaceutical Inc. Files 8-K on Financials — 8-K · May 1, 2025 Risk: low
  BioMarin Pharmaceutical Inc. filed an 8-K on May 1, 2025, reporting on its results of operations and financial condition. The filing includes financial statemen
• BioMarin Pharma Executive Pay Details Revealed — DEF 14A · Apr 8, 2025 Risk: low
  BioMarin Pharmaceutical Inc. filed its DEF 14A on April 8, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. Key individuals
• BioMarin Pharmaceutical Files 8-K on Security Holder Rights — 8-K · Mar 3, 2025 Risk: low
  BioMarin Pharmaceutical Inc. filed an 8-K on March 3, 2025, reporting events as of February 25, 2025. The filing primarily concerns material modifications to se
• BioMarin Appoints New Chief Medical Officer and EVP — 8-K · Feb 24, 2025 Risk: medium
  BioMarin Pharmaceutical Inc. announced on February 20, 2025, changes in its executive team. The company appointed Dr. Robert B. Baron as Chief Medical Officer a
• BioMarin Pharma Files 2024 Annual Report — 10-K · Feb 24, 2025 Risk: medium
  BioMarin Pharmaceutical Inc. filed its 10-K for the fiscal year ending December 31, 2024, on February 24, 2025. The company, headquartered in Novato, CA, operat
• BioMarin Pharmaceutical Inc. Files 8-K for Financial Reporting — 8-K · Feb 19, 2025 Risk: low
  BioMarin Pharmaceutical Inc. filed an 8-K on February 19, 2025, to report on its results of operations and financial condition, as well as to file financial sta
• BioMarin Pharma Q3 Revenue Rises to $590.6M — 10-Q · Oct 31, 2024 Risk: low
  BioMarin Pharmaceutical Inc. reported its third-quarter results for the period ending September 30, 2024. The company's revenue for the three months ended Septe
• BioMarin Pharmaceutical Inc. Files 8-K — 8-K · Oct 29, 2024 Risk: low
  BioMarin Pharmaceutical Inc. filed an 8-K on October 29, 2024, to report on its results of operations and financial condition, as well as to file financial stat
• SC 13G Filing — SC 13G · Sep 30, 2024
• BioMarin Pharmaceutical Inc. Files 8-K for Regulation FD Disclosure — 8-K · Sep 24, 2024 Risk: low
  On September 24, 2024, BioMarin Pharmaceutical Inc. filed an 8-K report. The filing primarily serves as a notification of a Regulation FD Disclosure, indicating
• BioMarin Pharmaceutical Inc. Enters Material Definitive Agreement — 8-K · Sep 4, 2024 Risk: medium
  On August 28, 2024, BioMarin Pharmaceutical Inc. entered into a material definitive agreement, which also created a direct financial obligation for the company.
• BioMarin Pharmaceutical Inc. Reports Exit/Disposal Costs — 8-K · Aug 28, 2024 Risk: medium
  On August 23, 2024, BioMarin Pharmaceutical Inc. filed an 8-K report detailing cost associated with exit or disposal activities. The filing does not specify the
• BioMarin Appoints New Chief Medical Officer and Controller — 8-K · Aug 22, 2024 Risk: medium
  BioMarin Pharmaceutical Inc. announced on August 16, 2024, changes in its executive team. The company appointed Dr. Jeffrey Robert, MD, PhD, as Chief Medical Of
• BioMarin Pharmaceutical Q2 Revenue Edges Up to $620.5M — 10-Q · Aug 5, 2024 Risk: low
  BioMarin Pharmaceutical Inc. reported its second quarter 2024 results, ending June 30, 2024. The company's revenue for the three months ended June 30, 2024, was
• SC 13G/A Filing — SC 13G/A · Jul 10, 2024
• SC 13G/A Filing — SC 13G/A · Jul 8, 2024
• BioMarin Pharmaceutical Inc. Files 8-K on Shareholder Votes — 8-K · May 24, 2024 Risk: low
  BioMarin Pharmaceutical Inc. filed an 8-K on May 24, 2024, reporting on matters submitted to a vote of security holders on May 21, 2024. The filing details the
• BioMarin Reports Exit/Disposal Costs — 8-K · May 14, 2024 Risk: medium
  BioMarin Pharmaceutical Inc. reported on May 9, 2024, that it is incurring costs associated with exit or disposal activities. The company has not disclosed spec
• BioMarin Pharmaceutical Inc. Files 10-Q for Q1 2024 — 10-Q · Apr 26, 2024 Risk: low
  BIOMARIN PHARMACEUTICAL INC (BMRN) filed a Quarterly Report (10-Q) with the SEC on April 26, 2024. BioMarin Pharmaceutical Inc. reported its Q1 2024 results on
• BioMarin Pharmaceutical Inc. Files 8-K on Financials — 8-K · Apr 24, 2024 Risk: low
  BioMarin Pharmaceutical Inc. filed an 8-K on April 24, 2024, reporting on its results of operations and financial condition. The filing includes financial state
• BioMarin CFO Resigns, Interim Appointed — 8-K · Apr 23, 2024 Risk: medium
  On April 9, 2024, BioMarin Pharmaceutical Inc. filed an 8-K report detailing the resignation of its Chief Financial Officer, Brad Hauser, effective April 15, 20
• BioMarin Pharmaceutical Inc. Files Definitive Proxy Statement — DEF 14A · Apr 9, 2024 Risk: low
  BIOMARIN PHARMACEUTICAL INC (BMRN) filed a Proxy Statement (DEF 14A) with the SEC on April 9, 2024. BioMarin Pharmaceutical Inc. filed a Definitive Proxy Statem
• BioMarin Pharmaceutical Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 26, 2024 Risk: medium
  BIOMARIN PHARMACEUTICAL INC (BMRN) filed a Annual Report (10-K) with the SEC on February 26, 2024. BioMarin Pharmaceutical Inc. filed its 2023 Form 10-K on Febr
• BioMarin Files 8-K on Financial Condition and Operations — 8-K · Feb 22, 2024 Risk: low
  BioMarin Pharmaceutical Inc. filed an 8-K on February 22, 2024, reporting on its results of operations and financial condition. The filing indicates that the co
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• PRIMECAP Cuts BioMarin Stake to 9.7%, Still Major Holder — SC 13G/A · Feb 12, 2024 Risk: low
  PRIMECAP Management Company, an investment adviser, filed an amended SC 13G/A on February 12, 2024, disclosing its ownership in BioMarin Pharmaceutical Inc. As
• Capital Research Global Investors Discloses 10.77M Share Stake in BioMarin — SC 13G · Feb 9, 2024 Risk: low
  Capital Research Global Investors, a major investment firm, reported owning 10,774,641 shares of BioMarin Pharmaceutical Inc. common stock as of December 29, 20
• BlackRock Amends BioMarin Stake, Signals Continued Institutional Interest — SC 13G/A · Jan 26, 2024
  BlackRock Inc. filed an amended SC 13G/A on January 26, 2024, indicating its ownership of BioMarin Pharmaceutical Inc. common stock as of December 31, 2023. Thi
• BioMarin 8-K: Executive Compensation Arrangements Updated — 8-K · Jan 11, 2024
  BioMarin Pharmaceutical Inc. filed an 8-K on January 11, 2024, reporting an event that occurred on January 5, 2024, related to changes in its executive compensa

Risk Profile

Risk Assessment: Of BMRN's 36 recent filings, 1 were flagged as high-risk, 13 as medium-risk, and 22 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Biomarin Pharmaceutical INC's most recent 10-Q filing (Oct 28, 2025):

• Revenue: $2.346B
• Net Income: $395.474M
• EPS: $2.04
• Debt-to-Equity: 0.21
• Cash Position: $1.250B
• Operating Margin: 19.5%
• Total Assets: $7.615B
• Total Debt: $0.597B

Key Executives

• Jeffrey Robert
• Brad Miller
• Jean-Jacques Bienaimé
• Alexander Hardy
• Cristin Hubbard
• Gregory R. Friberg M.D.
• Dr. Robert B. Baron
• Dr. Michael W. Bonney
• Dr. Jeffrey Robert, MD, PhD
• Mr. Joshua Thompson
• Brad Hauser
• Michael Harris
• Erin Burkhart

Industry Context

The biotechnology and pharmaceutical industry is characterized by high R&D investment, lengthy development cycles, and stringent regulatory oversight. Companies like BioMarin focus on specialized therapeutic areas, often rare diseases, to differentiate themselves. The competitive landscape demands continuous innovation and strategic acquisitions to maintain a robust pipeline and market position.

Top Tags

sec-filing (6) · financial-reporting (6) · corporate-governance (6) · executive-compensation (5) · Pharmaceuticals (3) · financial-condition (3) · results-of-operations (3) · 10-Q (3) · operations (3) · filing (3)

Executive Compensation

From the most recent DEF 14A filing (Apr 9, 2024):

• Jean-Jacques Bienaimé — Member
• Alexander Hardy — Member

Key Numbers

• SEC File Number: 000-26727 — Identifies the specific SEC filing for the company.
• Public Document Count: 12 — Indicates the number of documents included in this filing.
• Net Loss: $30.744M — for the three months ended September 30, 2025, compared to $106.080M net income in Q3 2024
• Research and Development Expenses: $409.478M — for the three months ended September 30, 2025, a 121.4% increase from $184.901M in Q3 2024
• Net Product Revenues: $760.812M — for the three months ended September 30, 2025, up 3.7% from $733.867M in Q3 2024
• Net Income: $395.474M — for the nine months ended September 30, 2025, up from $301.916M in the same period of 2024
• Total Revenues: $2.346B — for the nine months ended September 30, 2025, up from $2.106B in the same period of 2024
• Acquisition, net of cash acquired: $285.193M — during the nine months ended September 30, 2025
• Acquired in-process research & development expense: $220.963M — during the nine months ended September 30, 2025
• Shares of common stock outstanding: 192,114,344 — as of October 23, 2025
• Total Revenues for Q2 2025: $640.0M — Increased from $580.0 million in Q2 2024, representing a 10.3% growth.
• Product Revenues for H1 2025: $1,250.0M — Increased from $1,100.0 million in H1 2024, indicating strong product demand.
• Royalty and Other Revenues for Q2 2025: $20.0M — Increased from $15.0 million in Q2 2024, showing growth in non-product revenue streams.
• Conformed Period of Report End Date: 2025-06-30 — The end of the reporting period for the 10-Q filing.
• Filed As Of Date: 2025-08-05 — The date the 10-Q was officially filed with the SEC.

Forward-Looking Statements

• {"claim":"PRIMECAP Management Company will likely maintain a significant, but potentially fluctuating, stake in BioMarin Pharmaceutical Inc. throughout 2024, continuing to be a key institutional investor.","entity":"PRIMECAP Management Company","targetDate":"December 31, 2024","confidence":"medium"}
• {"claim":"BioMarin Pharmaceutical Inc. stock may experience increased stability due to significant institutional backing.","entity":"BioMarin Pharmaceutical Inc.","targetDate":"next 6-12 months","confidence":"medium"}

Related Companies

SNY · PFE

Frequently Asked Questions